Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer (Q33293591)

25 July 2017

1 reference

title

Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer (English)

1 reference

25 July 2017

1 reference

3

Matthew E Falagas

1 reference

25 July 2017

Evangelia Papadavid

1

1 reference

25 July 2017

Alexandros J Stratigos

series ordinal

2

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Pharmacotherapy

25 July 2017

published in

1 reference

25 July 2017

volume

8

1 reference

25 July 2017

issue

11

1 reference

25 July 2017

page(s)

1743-1755

1 reference

Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

The role of topical immune response modifiers in skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

The small-molecule immune response modifier imiquimod--its mode of action and clinical use in the treatment of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Immunomodulatory agents for prophylaxis and therapy of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

The therapeutic use of topical contact sensitizers in benign dermatoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Topical immunomodulators--progress towards treating inflammation, infection, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Immune response modifiers--mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Topical imiquimod: mechanism of action and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Immunomodulatory and pharmacologic properties of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Gene expression in actinic keratoses: pharmacological modulation by imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod: a topically applied link between innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream (Aldara).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Short‐course therapy with imiquimod 5% cream for solar keratoses: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Successful topical immunotherapy of bowenoid papulosis with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Topical 5% imiquimod for the therapy of actinic cheilitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod 5% cream in the treatment of Bowen's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Treatment of lentigo maligna with topical imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Topical imiquimod immunotherapy in the management of lentigo maligna

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Imiquimod in the treatment of lentigo maligna

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Topical imiquimod to treat recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

A case of severe eczema following use of imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.11.1743

10.1517/14656566.8.11.1743

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference